Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV003509090 | SCV005088915 | pathogenic | Mucopolysaccharidosis, MPS-II | 2024-06-07 | criteria provided, single submitter | literature only | Null variant (PVS1_VeryStrong), Prevalence of the variant significantly increased in affected individuals compared with controls (PS4_Supporting), Absent from controls (or at low frequency) in gnomAD database (PM2_Moderate), Patient’s phenotype or family history highly specific for the disease (PP4_Strong) |
| Labcorp Genetics |
RCV003509090 | SCV004299020 | pathogenic | Mucopolysaccharidosis, MPS-II | 2023-03-02 | criteria provided, single submitter | clinical testing | Disruption of this splice site has been observed in individual(s) with mucopolysaccharidosis II (PMID: 17063374, 30639582). Studies have shown that disruption of this splice site is associated with altered splicing resulting in multiple RNA products (PMID: 17063374). For these reasons, this variant has been classified as Pathogenic. This sequence change affects an acceptor splice site in intron 2 of the IDS gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in IDS are known to be pathogenic (PMID: 8940265, 9875019). This variant is not present in population databases (gnomAD no frequency). |